In preclinical models, the combination of the IDO inhibitor epacadostat and anti-PD-1/PD-L1 or anti-CTLA-4 antibodies suppressed tumor growth more effectively than the drug alone through reactivation of anti-cancer immunity (102). This evidence concerns the gene CD274 and neoplasm.